Brief: Revive Therapeutics Announces Published Research Results On Bucillamine As Potential Inhibitor Of COVID-19 Delta Variant
16/11/2021 11:16
Nov 16 (Reuters) - Revive Therapeutics Ltd RVV.CD :
* REVIVE THERAPEUTICS ANNOUNCES PUBLISHED RESEARCH RESULTS
ON
BUCILLAMINE AS POTENTIAL INHIBITOR OF SARS-COV-2 INFECTION DELTA
VARIANT
Source text for Eikon: ID:nGNX7ZhLBf
Further company coverage: RVV.CD
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Revive Therapeutics
See all newsBrief: Revive Therapeutics Provides Update Of Key Nerve Agent Countermeasure Study
Brief: Revive Therapeutics Provides Update Of Key Nerve Agent Countermeasure Study
Brief: Revive Therapeutics Announces Closing Of Second Tranche Of Private Placement
Brief: Revive Therapeutics Nears Completion Of Key Nerve Agent Countermeasure Study With Canadian Department Of National Defence
Brief: Revive Therapeutics Provides Update On Research Study Evaluating Bucillamine For Nerve Agent Exposure